[go: up one dir, main page]

WO2002085368A3 - Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders - Google Patents

Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders Download PDF

Info

Publication number
WO2002085368A3
WO2002085368A3 PCT/EP2002/004129 EP0204129W WO02085368A3 WO 2002085368 A3 WO2002085368 A3 WO 2002085368A3 EP 0204129 W EP0204129 W EP 0204129W WO 02085368 A3 WO02085368 A3 WO 02085368A3
Authority
WO
WIPO (PCT)
Prior art keywords
microcirculation disorders
treatment
human
prevention
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/004129
Other languages
French (fr)
Other versions
WO2002085368A2 (en
Inventor
Wolfgang Eisert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to MXPA03009506A priority Critical patent/MXPA03009506A/en
Priority to NZ529115A priority patent/NZ529115A/en
Priority to AU2002338396A priority patent/AU2002338396B2/en
Priority to JP2002582941A priority patent/JP2004525979A/en
Priority to EP02764059A priority patent/EP1389112A2/en
Priority to HU0303754A priority patent/HUP0303754A3/en
Priority to IL15809102A priority patent/IL158091A0/en
Priority to CA002444370A priority patent/CA2444370A1/en
Publication of WO2002085368A2 publication Critical patent/WO2002085368A2/en
Publication of WO2002085368A3 publication Critical patent/WO2002085368A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of treatment of the human or non-human animal body for treating NO-dependent microcirculation disorders is disclosed, for example microcirculation disorders caused by metabolic diseases, such as elevated levels of homocystin-homocystein inflammatory reactions or autoimmune diseases, furthermore peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation, which method comprises administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing a substance which scavenges free radicals, e.g. a pyrimido-pyrimidine selected from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof, and the use such substance for the manufacture of a corresponding pharmaceutical composition, optionally in combination with an agent capable of increasing NO production, more particularly HMG-CoA reductase inhibitors such as aspirin.
PCT/EP2002/004129 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders Ceased WO2002085368A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MXPA03009506A MXPA03009506A (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders.
NZ529115A NZ529115A (en) 2001-04-20 2002-04-13 Use of probucol, ascorbic acid, vitamin E, dipyridamole and mopidamol for treatment and prevention of NO-dependent microcirculation disorders
AU2002338396A AU2002338396B2 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
JP2002582941A JP2004525979A (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for the treatment and prevention of NO-dependent microcirculatory disorders
EP02764059A EP1389112A2 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
HU0303754A HUP0303754A3 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for preparation of pharmaceutical compsoition suitable for treatment and prevention of no-dependent microcirculation disorders
IL15809102A IL158091A0 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
CA002444370A CA2444370A1 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10119680A DE10119680A1 (en) 2001-04-20 2001-04-20 Use of scavenger compounds to treat and prevent no-dependent microcirculation disorders
DE10119680.6 2001-04-20

Publications (2)

Publication Number Publication Date
WO2002085368A2 WO2002085368A2 (en) 2002-10-31
WO2002085368A3 true WO2002085368A3 (en) 2003-02-20

Family

ID=7682292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004129 Ceased WO2002085368A2 (en) 2001-04-20 2002-04-13 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders

Country Status (10)

Country Link
EP (1) EP1389112A2 (en)
JP (1) JP2004525979A (en)
AU (1) AU2002338396B2 (en)
CA (1) CA2444370A1 (en)
DE (1) DE10119680A1 (en)
HU (1) HUP0303754A3 (en)
IL (1) IL158091A0 (en)
MX (1) MXPA03009506A (en)
NZ (1) NZ529115A (en)
WO (1) WO2002085368A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084912A1 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device method, and use for treatment of neuropathy involving nitric oxide
MD4341C1 (en) * 2013-11-21 2015-11-30 Ион МЕРЕУЦЭ Syrup for the treatment of gastric precancerous conditions
CN107106541A (en) 2015-01-28 2017-08-29 瑞采生技有限公司 Compounds for enhancing PPAR γ expression and nuclear translocation and medical uses thereof
CN113244395B (en) * 2020-02-10 2024-07-23 广州市妇女儿童医疗中心 Fibrosis disease mechanisms and therapeutic drugs

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457671A2 (en) * 1990-05-14 1991-11-21 FIDIA S.p.A. Dipyridamide for the treatment of diseases of the central or peripheral nervous system
SU1711892A1 (en) * 1989-01-06 1992-02-15 Московский медицинский стоматологический институт им.Н.А.Семашко Method of diabetic angioparhy treatment
SU1711894A1 (en) * 1989-08-08 1992-02-15 Детская Клиническая Больница N1 Method for treating the decompensated forms of stenosing laryngotracheitis in children
EP0543653A1 (en) * 1991-11-21 1993-05-26 Eli Lilly And Company Dipyridamole for the treatment of proliferative diseases
WO1995006470A1 (en) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
WO2000067737A2 (en) * 1999-05-07 2000-11-16 The Brigham And Women's Hospital, Inc. USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1711892A1 (en) * 1989-01-06 1992-02-15 Московский медицинский стоматологический институт им.Н.А.Семашко Method of diabetic angioparhy treatment
SU1711894A1 (en) * 1989-08-08 1992-02-15 Детская Клиническая Больница N1 Method for treating the decompensated forms of stenosing laryngotracheitis in children
EP0457671A2 (en) * 1990-05-14 1991-11-21 FIDIA S.p.A. Dipyridamide for the treatment of diseases of the central or peripheral nervous system
EP0543653A1 (en) * 1991-11-21 1993-05-26 Eli Lilly And Company Dipyridamole for the treatment of proliferative diseases
WO1995006470A1 (en) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
US5639482A (en) * 1993-11-10 1997-06-17 Crary; Ely J. Composition for control and prevention of diabetic retinopathy
WO2000067737A2 (en) * 1999-05-07 2000-11-16 The Brigham And Women's Hospital, Inc. USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
"Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group.", DIABETES, APR 1989, 38 (4) P491-8, UNITED STATES, XP002130771 *
AMERICAN FAMILY PHYSICIAN. UNITED STATES MAR 1993, vol. 47, no. 4, March 1993 (1993-03-01), pages 823 - 829, ISSN: 0002-838X *
AMERICAN JOURNAL OF HYPERTENSION: JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION. UNITED STATES JUN 1996, vol. 9, no. 6, June 1996 (1996-06-01), pages 577 - 590, ISSN: 0895-7061 *
BANGLADESH MEDICAL RESEARCH COUNCIL BULLETIN. BANGLADESH DEC 1989, vol. 15, no. 2, December 1989 (1989-12-01), pages 47 - 59, ISSN: 0377-9238 *
CARDIOVASCULAR SURGERY (LONDON, ENGLAND) ENGLAND APR 1998, vol. 6, no. 2, April 1998 (1998-04-01), pages 178 - 187, ISSN: 0967-2109 *
CLINICAL AND INVESTIGATIVE MEDICINE. MEDECINE CLINIQUE ET EXPERIMENTALE. CANADA AUG 1989, vol. 12, no. 4, August 1989 (1989-08-01), pages 235 - 240, ISSN: 0147-958X *
CONNOLLY, J. P. ET AL: "Peripheral vasodilators and the management of peripheral vascular disease and Raynaud's syndrome in general practice", PHARMACOEPIDEMIOL. DRUG SAF., 1998, 7, 189-196, XP002130772 *
DATABASE MEDLINE [online] April 1998 (1998-04-01), YOSHIDA W B ET AL: "Effect of alpha-tocopherol, taurine and selenium on the attenuation of ischemia/reperfusion injury of splanchnic organs.", XP002213339, Database accession no. NLM9610832 *
DATABASE MEDLINE [online] April 1999 (1999-04-01), DENTON C P ET AL: "Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.", XP002213234, Database accession no. NLM10378706 *
DATABASE MEDLINE [online] August 1989 (1989-08-01), LANGLEBEN D ET AL: "Effects of dimethylthiourea on chronic hypoxia-induced pulmonary arterial remodelling and ventricular hypertrophy in rats.", XP002213341, Database accession no. NLM2535591 *
DATABASE MEDLINE [online] December 1989 (1989-12-01), ALI S M ET AL: "Role of plasma ascorbate in diabetic microangiopathy.", XP002213238, Database accession no. NLM2629696 *
DATABASE MEDLINE [online] December 2001 (2001-12-01), BERTUGLIA S ET AL: "Glucose-insulin-potassium treatment in combination with dipyridamole inhibits ischaemia-reperfusion-induced damage.", XP002213342, Database accession no. NLM11793017 *
DATABASE MEDLINE [online] July 1994 (1994-07-01), BALLMER P E ET AL: "[Antioxidant vitamins and disease--risk of a suboptimal supply]", XP002213237, Database accession no. NLM8073383 *
DATABASE MEDLINE [online] June 1996 (1996-06-01), SHARMA R C ET AL: "Probucol suppresses oxidant stress in hypertensive arteries. Immunohistochemical evidence.", XP002213235, Database accession no. NLM8783783 *
DATABASE MEDLINE [online] March 1993 (1993-03-01), ADEE A C: "Managing Raynaud's phenomenon: a practical approach.", XP002213236, Database accession no. NLM8438681 *
DATABASE MEDLINE [online] November 1994 (1994-11-01), KEMPSKI O S: "[Neuroprotection. Models and basic principles]", XP002213340, Database accession no. NLM7840411 *
DATABASE WPI Section Ch Week 199252, Derwent World Patents Index; Class B05, AN 1992-431746, XP002213240 *
DATABASE WPI Section Ch Week 199252, Derwent World Patents Index; Class B05, AN 1992-431748, XP002213239 *
DER ANAESTHESIST. GERMANY NOV 1994, vol. 43 Suppl 2, November 1994 (1994-11-01), pages S25 - S33, ISSN: 0003-2417 *
DIABETOLOGIA. GERMANY DEC 2001, vol. 44, no. 12, December 2001 (2001-12-01), pages 2165 - 2170, ISSN: 0012-186X *
KAISER H J ET AL: "SHORT-TERM EFFECT OF DIPYRIDAMOLE ON BLOOD FLOW VELOCITIES IN THE EXTRAOCULAR VESSELS", INTERNATIONAL OPHTHALMOLOGY,NL,NIJHOFF/JUNK, DORDRECHT, vol. 19, no. 6, 1 January 1996 (1996-01-01), pages 355 - 358, XP000650843, ISSN: 0165-5701 *
MARMONT AM ET AL: "Thrombotic thrombocytopenic purpura successfully treated with a combination of dipyridamole and aspirin.", HAEMATOLOGICA, APR 1980, 65 (2) P222-31, ITALY, XP002130770 *
RHEUMATOLOGY (OXFORD, ENGLAND) ENGLAND APR 1999, vol. 38, no. 4, April 1999 (1999-04-01), pages 309 - 315, ISSN: 1462-0324 *
THERAPEUTISCHE UMSCHAU. REVUE THERAPEUTIQUE. SWITZERLAND JUL 1994, vol. 51, no. 7, July 1994 (1994-07-01), pages 467 - 474, ISSN: 0040-5930 *

Also Published As

Publication number Publication date
AU2002338396B2 (en) 2007-10-18
DE10119680A1 (en) 2002-11-14
MXPA03009506A (en) 2004-02-12
HUP0303754A3 (en) 2006-02-28
CA2444370A1 (en) 2002-10-31
EP1389112A2 (en) 2004-02-18
NZ529115A (en) 2005-08-26
WO2002085368A2 (en) 2002-10-31
IL158091A0 (en) 2004-03-28
JP2004525979A (en) 2004-08-26
HUP0303754A2 (en) 2004-03-01

Similar Documents

Publication Publication Date Title
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
YU30002A (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
EP1510221A4 (en) PREVENTIVE AND / OR THERAPEUTIC MEANS FOR SUBJECTS HAVING THE EXPRESSION OR ACTIVATION OF HER2 AND / OR EGFR
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
NO20071512L (en) Therapeutic combinations comprising poly (ADP-ribose) polymerase inhibitor.
WO2006042150A8 (en) Diaminoalkane aspartic protease inhibitors
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
CY1109773T1 (en) MEDICATIONS FOR DISEASES OF JOINTS
EE05423B1 (en) Use of an IL-18 inhibitor for the manufacture of a medicament for the treatment or prevention of liver injury and other diseases, the use of a vector and a cell in the manufacture of an inhibitor, and a pharmaceutical composition comprising an IL-18 inhibitor.
EA200501690A1 (en) COMPOSITION INCLUDING PDE4 INHIBITOR AND PDE5 INHIBITOR
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2004093881A3 (en) Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2002085368A3 (en) Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
WO2004069254A3 (en) Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders
ATE550039T1 (en) AGENTS FOR THE TREATMENT OF GLOMERULAR DISEASES
WO2007147497A3 (en) Use of a disintegrin-like and metalloproteinase with thrombospondin type 1 motif (adamts1) as a therapeutic or diagnostic target
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
BRPI0408500A (en) Type 1 diabetes treatment with pde5 inhibitors
TW200509945A (en) Agent for treatment of anal disease
WO2005035500A3 (en) Therapeutic agents useful for treating pain
WO2003066806A3 (en) Therapeutic use of aziridino compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 158091

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002764059

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002338396

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2444370

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/009506

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002582941

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 529115

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2002764059

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 529115

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 529115

Country of ref document: NZ